Circulating MicroRNA-122 as a Potential Biomarker for Hepatitis C Virus Induced Hepatocellular Carcinoma

IF 0.4 Q4 ONCOLOGY International Journal of Cancer Management Pub Date : 2022-11-09 DOI:10.5812/ijcm-131221
A. Malik, Prajjalendra Barooah, Snigdha Saikia, Subhash Medhi, S. Kalita, Manas Jyoti Kalita, P. Das, K. Dutta, Pooja Bharali, M. Sarma, Preeti Sarma, M. Bhattacharyya, P. Kar, B. Goswami, Musaed Alkholief, A. Alshamsan
{"title":"Circulating MicroRNA-122 as a Potential Biomarker for Hepatitis C Virus Induced Hepatocellular Carcinoma","authors":"A. Malik, Prajjalendra Barooah, Snigdha Saikia, Subhash Medhi, S. Kalita, Manas Jyoti Kalita, P. Das, K. Dutta, Pooja Bharali, M. Sarma, Preeti Sarma, M. Bhattacharyya, P. Kar, B. Goswami, Musaed Alkholief, A. Alshamsan","doi":"10.5812/ijcm-131221","DOIUrl":null,"url":null,"abstract":"Background: The microRNA (miRNA) mediated translational repression can cause various diseases in humans. The liver-specific miRNA (microRNA-122 (miR-122)) is primarily involved in tissue tropism during hepatitis C virus (HCV) infection which ultimately leads to hepatocellular carcinoma (HCC). Objectives: This study focuses on evaluating host serum miR-122 as a prognostic marker in HCV-induced hepatocellular carcinoma. Methods: Evaluation of miR-122 expression was carried out by quantitative real time PCR. Results: Positive expression of miR-122 was observed in patients with chronic hepatitis C (CHC) followed by HCC patients compared to healthy controls. A difference in median levels of the miR-122 expression in CHC and HCC patients (P < 0.000) was found in contrast to cirrhosis patients (P = 0.511). The serum miR-122 expression was found threefold higher in liver cirrhosis patients than chronic hepatitis. Further, the area under the receiver operating characteristic curve (AUROC) analysis of miR-122 expression profile can efficiently distinguish CHC patients (AUROC = 0.978, P = 0.000, 95% confidence interval (CI) = 0.958 to 0.998) and HCC from healthy controls (AUROC = 0.971, P = 0.000, 95% CI = 0.944 to 0.997). Moreover, receiver operating characteristic (ROC) curve analysis significantly distinguished between CHC patients from cirrhosis patients (AUROC = 0.955, P = 0.000, 95% CI = 0.925 to 0.986) but not CHC from HCC patients (AUROC = 0.584, P = 0.104, 95% CI = 0.485 to 0.684). This study revealed a substantial correlation of miR-122 with HCV viral load (r = 0.56, P = 0.000), ALT (r = 0.67, P = 0.000) and AST (r = 0.65, P = 0.000) levels. Conclusions: Serum miR-122 can potentially serve as a promising prognostic tool for HCV induced HCC.","PeriodicalId":44764,"journal":{"name":"International Journal of Cancer Management","volume":null,"pages":null},"PeriodicalIF":0.4000,"publicationDate":"2022-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Cancer Management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5812/ijcm-131221","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 1

Abstract

Background: The microRNA (miRNA) mediated translational repression can cause various diseases in humans. The liver-specific miRNA (microRNA-122 (miR-122)) is primarily involved in tissue tropism during hepatitis C virus (HCV) infection which ultimately leads to hepatocellular carcinoma (HCC). Objectives: This study focuses on evaluating host serum miR-122 as a prognostic marker in HCV-induced hepatocellular carcinoma. Methods: Evaluation of miR-122 expression was carried out by quantitative real time PCR. Results: Positive expression of miR-122 was observed in patients with chronic hepatitis C (CHC) followed by HCC patients compared to healthy controls. A difference in median levels of the miR-122 expression in CHC and HCC patients (P < 0.000) was found in contrast to cirrhosis patients (P = 0.511). The serum miR-122 expression was found threefold higher in liver cirrhosis patients than chronic hepatitis. Further, the area under the receiver operating characteristic curve (AUROC) analysis of miR-122 expression profile can efficiently distinguish CHC patients (AUROC = 0.978, P = 0.000, 95% confidence interval (CI) = 0.958 to 0.998) and HCC from healthy controls (AUROC = 0.971, P = 0.000, 95% CI = 0.944 to 0.997). Moreover, receiver operating characteristic (ROC) curve analysis significantly distinguished between CHC patients from cirrhosis patients (AUROC = 0.955, P = 0.000, 95% CI = 0.925 to 0.986) but not CHC from HCC patients (AUROC = 0.584, P = 0.104, 95% CI = 0.485 to 0.684). This study revealed a substantial correlation of miR-122 with HCV viral load (r = 0.56, P = 0.000), ALT (r = 0.67, P = 0.000) and AST (r = 0.65, P = 0.000) levels. Conclusions: Serum miR-122 can potentially serve as a promising prognostic tool for HCV induced HCC.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
循环MicroRNA-122作为丙型肝炎病毒诱导的肝细胞癌的潜在生物标志物
背景:miRNA介导的翻译抑制可引起人类多种疾病。肝脏特异性miRNA (microRNA-122 (miR-122))主要参与丙型肝炎病毒(HCV)感染期间的组织趋向性,最终导致肝细胞癌(HCC)。目的:本研究的重点是评估宿主血清miR-122作为hcv诱导的肝细胞癌的预后标志物。方法:采用实时荧光定量PCR法检测miR-122的表达。结果:与健康对照组相比,miR-122在慢性丙型肝炎(CHC)患者和HCC患者中呈阳性表达。与肝硬化患者相比,CHC和HCC患者miR-122的中位表达水平存在差异(P < 0.000) (P = 0.511)。肝硬化患者血清miR-122表达比慢性肝炎患者高3倍。此外,miR-122表达谱的受试者工作特征曲线下面积(AUROC)分析可以有效区分CHC患者(AUROC = 0.978, P = 0.000, 95%可信区间(CI) = 0.958 ~ 0.998)和健康对照组的HCC (AUROC = 0.971, P = 0.000, 95% CI = 0.944 ~ 0.997)。此外,受试者工作特征(ROC)曲线分析在CHC患者与肝硬化患者之间有显著差异(AUROC = 0.955, P = 0.000, 95% CI = 0.925 ~ 0.986),而HCC患者之间无显著差异(AUROC = 0.584, P = 0.104, 95% CI = 0.485 ~ 0.684)。本研究显示miR-122与HCV病毒载量(r = 0.56, P = 0.000)、ALT (r = 0.67, P = 0.000)和AST (r = 0.65, P = 0.000)水平存在显著相关性。结论:血清miR-122可能作为HCV诱导的HCC的预后工具。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
1.10
自引率
0.00%
发文量
67
期刊介绍: International Journal of Cancer Management (IJCM) publishes peer-reviewed original studies and reviews on cancer etiology, epidemiology and risk factors, novel approach to cancer management including prevention, diagnosis, surgery, radiotherapy, medical oncology, and issues regarding cancer survivorship and palliative care. The scope spans the spectrum of cancer research from the laboratory to the clinic, with special emphasis on translational cancer research that bridge the laboratory and clinic. We also consider original case reports that expand clinical cancer knowledge and convey important best practice messages.
期刊最新文献
Assessing Analgesic Adherence and Influencing Factors in Saudi Cancer Patients Research Progress of Idiopathic Pulmonary Fibrosis Complicated with Lung Cancer Microvessel Density Assessment and Related Factors in Patients with Endometrial Cancer: A Cross-Sectional Study Challenges of Truth-telling to Patients and Their Families: A Qualitative Study Continued Increase in Incidence of Kidney Cancer in Iran and its 31 Provinces
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1